187 related articles for article (PubMed ID: 19508176)
1. Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).
Heffeter P; Popovic-Bijelic A; Saiko P; Dornetshuber R; Jungwirth U; Voevodskaya N; Biglino D; Jakupec MA; Elbling L; Micksche M; Szekeres T; Keppler BK; Gräslund A; Berger W
Curr Cancer Drug Targets; 2009 Aug; 9(5):595-607. PubMed ID: 19508176
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24).
Heffeter P; Jakupec MA; Körner W; Wild S; von Keyserlingk NG; Elbling L; Zorbas H; Korynevska A; Knasmüller S; Sutterlüty H; Micksche M; Keppler BK; Berger W
Biochem Pharmacol; 2006 Feb; 71(4):426-40. PubMed ID: 16343446
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
Heffeter P; Jakupec MA; Körner W; Chiba P; Pirker C; Dornetshuber R; Elbling L; Sutterlüty H; Micksche M; Keppler BK; Berger W
Biochem Pharmacol; 2007 Jun; 73(12):1873-86. PubMed ID: 17445775
[TBL] [Abstract][Full Text] [Related]
4. The 2,2'-bipyridyl-6-carbothioamide copper (II) complex differs from the iron (II) complex in its biochemical effects in tumor cells, suggesting possible differences in the mechanism leading to cytotoxicity.
Nocentini G; Barzi A
Biochem Pharmacol; 1996 Jul; 52(1):65-71. PubMed ID: 8678909
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea.
Chitambar CR; Matthaeus WG; Antholine WE; Graff K; O'Brien WJ
Blood; 1988 Dec; 72(6):1930-6. PubMed ID: 3058232
[TBL] [Abstract][Full Text] [Related]
6. The role of iron in cell cycle progression and the proliferation of neoplastic cells.
Le NT; Richardson DR
Biochim Biophys Acta; 2002 Oct; 1603(1):31-46. PubMed ID: 12242109
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
[TBL] [Abstract][Full Text] [Related]
8. Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis.
Chitambar CR; Wereley JP
Cancer Res; 1995 Oct; 55(19):4361-6. PubMed ID: 7671248
[TBL] [Abstract][Full Text] [Related]
9. 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
Nocentini G; Federici F; Franchetti P; Barzi A
Cancer Res; 1993 Jan; 53(1):19-26. PubMed ID: 8416745
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of P388 murine leukemia cells to hydroxyurea cytotoxicity by hydrophobic iron-chelating agents.
Satyamoorthy K; Chitnis M; Basrur V
Anticancer Res; 1986; 6(2):329-33. PubMed ID: 3518597
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of 2,2'-bipyridyl-6-carbothioamide: a ribonucleotide reductase inhibitor.
Nocentini G; Barzi A
Gen Pharmacol; 1997 Nov; 29(5):701-6. PubMed ID: 9347313
[TBL] [Abstract][Full Text] [Related]
12. A novel iron(II) phenanthroline complex exhibits anticancer activity against TFR1-overexpressing esophageal squamous cell carcinoma cells through ROS accumulation and DNA damage.
Ye J; Ma J; Liu C; Huang J; Wang L; Zhong X
Biochem Pharmacol; 2019 Aug; 166():93-107. PubMed ID: 31078603
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
14. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.
Shao J; Zhou B; Zhu L; Bilio AJ; Su L; Yuan YC; Ren S; Lien EJ; Shih J; Yen Y
Biochem Pharmacol; 2005 Feb; 69(4):627-34. PubMed ID: 15670581
[TBL] [Abstract][Full Text] [Related]
15. Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase.
Kayyali R; Porter JB; Liu ZD; Davies NA; Nugent JH; Cooper CE; Hider RC
J Biol Chem; 2001 Dec; 276(52):48814-22. PubMed ID: 11602611
[TBL] [Abstract][Full Text] [Related]
16. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators.
Nyholm S; Mann GJ; Johansson AG; Bergeron RJ; Gräslund A; Thelander L
J Biol Chem; 1993 Dec; 268(35):26200-5. PubMed ID: 8253740
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea-induced conversion of mammalian ribonucleotide reductase to a form hypersensitive to bleomycin.
McClarty GA; Chan AK; Wright JA
Cancer Res; 1986 Sep; 46(9):4516-21. PubMed ID: 2425956
[TBL] [Abstract][Full Text] [Related]
18. May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?
Matos CP; Adiguzel Z; Yildizhan Y; Cevatemre B; Onder TB; Cevik O; Nunes P; Ferreira LP; Carvalho MD; Campos DL; Pavan FR; Pessoa JC; Garcia MH; Tomaz AI; Correia I; Acilan C
Eur J Med Chem; 2019 Aug; 176():492-512. PubMed ID: 31132480
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of the subunits of ribonucleotide reductase as a new approach to combination chemotherapy.
Cory JG; Sato A; Lasater L
Adv Enzyme Regul; 1980; 19():139-50. PubMed ID: 7039256
[No Abstract] [Full Text] [Related]
20. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase.
Cooper CE; Lynagh GR; Hoyes KP; Hider RC; Cammack R; Porter JB
J Biol Chem; 1996 Aug; 271(34):20291-9. PubMed ID: 8702762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]